Onco-Innovations Targets Next Wave of DNA Damage Response Cancer Therapies Beyond PARP Inhibitors

Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) is positioning itself as an early leader in a novel class of cancer therapeutics targeting the DNA Damage Response (DDR) pathway, according to a BioMedWire editorial. The company is advancing ONC010, a nanoparticle-encapsulated inhibitor of polynucleotide kinase/phosphatase (PNKP), an enzyme involved in multiple DNA repair pathways. This approach aims to overcome limitations of existing PARP inhibitors by addressing a broader range of DNA repair mechanisms.

Preclinical data highlighted in the editorial demonstrate that ONC010 more than doubled median survival in PTEN-deficient colorectal cancer animal models while exhibiting a favorable toxicity profile. PTEN deficiency is a common genetic alteration in cancer, and these results suggest ONC010 may offer a targeted therapy for patients with limited treatment options. Onco-Innovations holds exclusive global rights to a foundational portfolio of PNKP inhibitor technology, which it aims to develop as a first-in-class therapeutic.

The company is progressing ONC010 through manufacturing scale-up and IND-enabling studies, with plans for first-in-human clinical development. This work is supported by its proprietary SynoGraph causal AI platform through subsidiary Inka Health. The editorial also reviewed recent developments across the oncology sector, including AstraZeneca plc (NYSE: AZN), Aprea Therapeutics Inc. (NASDAQ: APRE), Boundless Bio Inc. (NASDAQ: BOLD), and Foghorn Therapeutics Inc. (NASDAQ: FHTX), highlighting the growing interest in DDR-targeted therapies.

According to the editorial, the DDR inhibitor market is rapidly expanding as new drug classes emerge beyond PARP inhibitors. Onco-Innovations' focus on PNKP inhibition positions it at the forefront of this next wave of cancer therapies. The company's technology aims to selectively kill cancer cells by exploiting defects in DNA repair pathways, potentially improving efficacy and reducing side effects compared to conventional treatments.

For more information, see the full press release at https://ibn.fm/HH1VP. Updates on the company are available in its newsroom at https://ibn.fm/ONNVF.